Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease

被引:102
作者
Noguchi, M [1 ]
Hiwatashi, N [1 ]
Liu, Z [1 ]
Toyota, T [1 ]
机构
[1] Tohoku Univ, Sch Med, Dept Internal Med 3, Aoba Ku, Sendai, Miyagi 98077, Japan
关键词
Crohn's disease; inflammation; mucosal immunology; soluble TNF receptor; tumour necrosis factor; ulcerative colitis;
D O I
10.1136/gut.43.2.203
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background-Tumour necrosis factor (TNF) alpha and TNF-beta are soluble ligands binding to TNF receptors with similar activities; soluble TNF receptors neutralise TNF activity by acting as inhibitors. Little is known about the cytokine/soluble receptor role in inflammatory bowel disease (IBD). Aims-To test the hypothesis that an imbalance in secretion between TNF and TNF inhibitors plays a role in gut inflammation in patients with IBD. Methods-The secretion of TNF-alpha, TNF-beta, and soluble TNF receptors was compared in the culture supernatants of colonic biopsy specimens and isolated lamina propria mononuclear cells from patients with active colonic IBD. Results-Spontaneous secretion of TNF-alpha in involved IBD mucosa was higher than in normal control and self limited colitis mucosa. Secretion of TNF-beta was higher in patients with Crohn's disease than in those with ulcerative colitis. Soluble TNF receptor in IBD mucosa inhibited TNF activity. Type 2 soluble receptor release from IBD mucosa was increased in active inflammation; release from lamina propria cells was not increased. Mucosal TNF-alpha production correlated with severity of disease. Conclusions-Results showed enhanced secretion of TNF-alpha but failure to release enhanced amounts of soluble TNF receptor in lamina propria mononuclear cells of patients with IBD. An imbalance in secretion between TNF and TNF inhibitor may be implicated in the pathogenesis of IBD.
引用
收藏
页码:203 / 209
页数:7
相关论文
共 50 条
  • [41] TAKASUKA N, 1991, J IMMUNOL, V146, P3824
  • [42] A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
    Targan, SR
    Hanauer, SB
    vanDeventer, SJH
    Mayer, L
    Present, DH
    Braakman, T
    DeWoody, KL
    Schaible, TF
    Rutgeerts, PJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (15) : 1029 - 1035
  • [43] TORIMOTO K, 1990, AM J PATHOL, V137, P1103
  • [44] CORTISONE IN ULCERATIVE COLITIS - FINAL REPORT ON A THERAPEUTIC TRIAL
    TRUELOVE, SC
    WITTS, LJ
    [J]. BRITISH MEDICAL JOURNAL, 1955, 2 (OCT29) : 1041 - 1048
  • [45] Tumour necrosis factor and Crohn's disease
    VanDeventer, SJH
    [J]. GUT, 1997, 40 (04) : 443 - 448
  • [46] TREATMENT OF CROHNS-DISEASE WITH ANTITUMOR NECROSIS FACTOR CHIMERIC MONOCLONAL-ANTIBODY (CA2)
    VANDULLEMEN, HM
    VANDEVENTER, SJH
    HOMMES, DW
    BIJL, HA
    JANSEN, J
    TYTGAT, GNJ
    WOODY, J
    [J]. GASTROENTEROLOGY, 1995, 109 (01) : 129 - 135
  • [47] AN INDEX OF INFLAMMATORY ACTIVITY IN PATIENTS WITH CROHNS-DISEASE
    VANHEES, PAM
    VANELTEREN, PH
    VANLIER, HJJ
    VANTONGEREN, JHM
    [J]. GUT, 1980, 21 (04) : 279 - 286
  • [48] TUMOR-NECROSIS-FACTOR SOLUBLE RECEPTORS CIRCULATE DURING EXPERIMENTAL AND CLINICAL INFLAMMATION AND CAN PROTECT AGAINST EXCESSIVE TUMOR-NECROSIS-FACTOR-ALPHA INVITRO AND INVIVO
    VANZEE, KJ
    KOHNO, T
    FISCHER, E
    ROCK, CS
    MOLDAWER, LL
    LOWRY, SF
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (11) : 4845 - 4849
  • [49] Thalidomide in Crohn's disease
    Wettstein, AR
    Meagher, AP
    [J]. LANCET, 1997, 350 (9089) : 1445 - 1446
  • [50] INTESTINAL PERMEABILITY AND THE PREDICTION OF RELAPSE IN CROHNS-DISEASE
    WYATT, J
    VOGELSANG, H
    HUBL, W
    WALDHOER, T
    LOCHS, H
    [J]. LANCET, 1993, 341 (8858) : 1437 - 1439